Back

Edoxaban dose, frailty, and outcomes in patients with atrial fibrillation: the ETNA-AF-Europe 4-year follow-up

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiovascular outcome studies in the elderly Cardiovascular Disease in the Elderly ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Associate Professor Stefano Fumagalli

Internal and Specialist Medicine and Geriatric Arrhythmia Unit, Florence (Italy)

6 More presentations in this session

Presentation thumbnail
The long-term clinical benefit of early versus delayed invasive strategies in elderly patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention
Assistant Professor J. Choe (Pusan, KR)
Abstract Slides Video
Presentation thumbnail
Clinical prediction model of main adverse cardiovascular and cerebrovascular events for elderly patients with acute coronary syndrome
Doctor J. Xu (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Relative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against hospitalizations and mortality according to frailty score: a post-hoc analysis of the DANFLU-1 trial
Doctor C. Espersen (Gentofte, DK)
Abstract Slides Video
Presentation thumbnail
Clinical management and outcomes of patients with infective endocarditis according to frailty status
Doctor C. Perez Garcia (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Risk of death, thromboembolic events, and bleeding in elderly patients with Atrial Fibrillation and Clinical Complexity who are not taking oral anticoagulation.
Doctor T. Bucci (Perugia, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular outcome studies in the elderly

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe programme
thumbnail
Congress Presentation
Frailty and anticoagulant prescription in older hospitalized patients with atrial fibrillation: a multi-centred observational study
thumbnail
Congress Presentation
Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources